Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Ubiquitylation is a reversible post-translational modification of proteins that controls a myriad of functions and cellular processes. It occurs through the sequential action of three distinct enzymes. E3 ubiquitin ligases (E3s) play the role of conductors of the ubiquitylation pathway making them a...
Gespeichert in:
| Veröffentlicht in: | Biochimie 2016-03, Vol.122, p.339-347 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | |
| container_start_page | 339 |
| container_title | Biochimie |
| container_volume | 122 |
| creator | Lamsoul, Isabelle Uttenweiler-Joseph, Sandrine Moog-Lutz, Christel Lutz, Pierre G. |
| description | Ubiquitylation is a reversible post-translational modification of proteins that controls a myriad of functions and cellular processes. It occurs through the sequential action of three distinct enzymes. E3 ubiquitin ligases (E3s) play the role of conductors of the ubiquitylation pathway making them attractive therapeutic targets. This review is dedicated to the largest family of multimeric E3s, the Cullin-RING E3 (CRL) family and more specifically to cullin 5 based CRLs that remains poorly characterized.
•CRLs are key players of the ubiquitylation pathway.•CRL activity is highly regulated.•CRL5s targeted specific protein substrates to degradation by the proteasome.•CRLs that belong to the largest family of E3s represent promising drug targets. |
| doi_str_mv | 10.1016/j.biochi.2015.08.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02406392v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300908415002503</els_id><sourcerecordid>1764339803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c512t-89d11a09de35e827d0fd260e29a9d1009ac7c3e7c5cdaa498a481b970973a6a33</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobn78A5FeKth6krRpAqKMoW4wFESvQ5aebRndOpN24r-3s-qlVwfOed73wEPIGYWEAhXXy2TqKrtwCQOaJSATAL5H-lRwGQsq-T7pAweIFci0R45CWAJABkwdkh4TLONC8T65GTZl6dZRFr-Mnx6jex41U_feuLrdlW5uAoaraI0fUb1AbzbY1M5GtfFzrMPdCTmYmTLg6c88Jm8P96_DUTx5fhwPB5PYZpTVsVQFpQZUgTxDyfICZgUTgEyZ9gKgjM0tx9xmtjAmVdKkkk5VDirnRhjOj8ll17swpd54tzL-U1fG6dFgonc7YCkIrtiWtuxFx2589d5gqPXKBYtladZYNUHTXKScKwm72rRDra9C8Dj766agd471UneO9c6xBqnhO3b-86GZrrD4C_1KbYHbDsDWydah18E6XFssnEdb66Jy_3_4AgcHi-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1764339803</pqid></control><display><type>article</type><title>Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lamsoul, Isabelle ; Uttenweiler-Joseph, Sandrine ; Moog-Lutz, Christel ; Lutz, Pierre G.</creator><creatorcontrib>Lamsoul, Isabelle ; Uttenweiler-Joseph, Sandrine ; Moog-Lutz, Christel ; Lutz, Pierre G.</creatorcontrib><description>Ubiquitylation is a reversible post-translational modification of proteins that controls a myriad of functions and cellular processes. It occurs through the sequential action of three distinct enzymes. E3 ubiquitin ligases (E3s) play the role of conductors of the ubiquitylation pathway making them attractive therapeutic targets. This review is dedicated to the largest family of multimeric E3s, the Cullin-RING E3 (CRL) family and more specifically to cullin 5 based CRLs that remains poorly characterized.
•CRLs are key players of the ubiquitylation pathway.•CRL activity is highly regulated.•CRL5s targeted specific protein substrates to degradation by the proteasome.•CRLs that belong to the largest family of E3s represent promising drug targets.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2015.08.003</identifier><identifier>PMID: 26253693</identifier><language>eng</language><publisher>France: Elsevier B.V</publisher><subject>Antineoplastic Agents - therapeutic use ; Cullin Proteins - metabolism ; Cullin RING ligase ; E3 ubiquitin ligase ; Humans ; Life Sciences ; Models, Biological ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Proteasome Endopeptidase Complex - metabolism ; Signal Transduction - drug effects ; Therapeutic targets ; Ubiquitin - metabolism ; Ubiquitin-proteasome system ; Ubiquitin-Protein Ligases - metabolism ; Ubiquitination</subject><ispartof>Biochimie, 2016-03, Vol.122, p.339-347</ispartof><rights>2015 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM)</rights><rights>Copyright © 2015 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c512t-89d11a09de35e827d0fd260e29a9d1009ac7c3e7c5cdaa498a481b970973a6a33</citedby><cites>FETCH-LOGICAL-c512t-89d11a09de35e827d0fd260e29a9d1009ac7c3e7c5cdaa498a481b970973a6a33</cites><orcidid>0000-0002-7769-5627 ; 0000-0001-9019-4766 ; 0000-0003-0590-9101</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biochi.2015.08.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26253693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02406392$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamsoul, Isabelle</creatorcontrib><creatorcontrib>Uttenweiler-Joseph, Sandrine</creatorcontrib><creatorcontrib>Moog-Lutz, Christel</creatorcontrib><creatorcontrib>Lutz, Pierre G.</creatorcontrib><title>Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Ubiquitylation is a reversible post-translational modification of proteins that controls a myriad of functions and cellular processes. It occurs through the sequential action of three distinct enzymes. E3 ubiquitin ligases (E3s) play the role of conductors of the ubiquitylation pathway making them attractive therapeutic targets. This review is dedicated to the largest family of multimeric E3s, the Cullin-RING E3 (CRL) family and more specifically to cullin 5 based CRLs that remains poorly characterized.
•CRLs are key players of the ubiquitylation pathway.•CRL activity is highly regulated.•CRL5s targeted specific protein substrates to degradation by the proteasome.•CRLs that belong to the largest family of E3s represent promising drug targets.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cullin Proteins - metabolism</subject><subject>Cullin RING ligase</subject><subject>E3 ubiquitin ligase</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Models, Biological</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Proteasome Endopeptidase Complex - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Therapeutic targets</subject><subject>Ubiquitin - metabolism</subject><subject>Ubiquitin-proteasome system</subject><subject>Ubiquitin-Protein Ligases - metabolism</subject><subject>Ubiquitination</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobn78A5FeKth6krRpAqKMoW4wFESvQ5aebRndOpN24r-3s-qlVwfOed73wEPIGYWEAhXXy2TqKrtwCQOaJSATAL5H-lRwGQsq-T7pAweIFci0R45CWAJABkwdkh4TLONC8T65GTZl6dZRFr-Mnx6jex41U_feuLrdlW5uAoaraI0fUb1AbzbY1M5GtfFzrMPdCTmYmTLg6c88Jm8P96_DUTx5fhwPB5PYZpTVsVQFpQZUgTxDyfICZgUTgEyZ9gKgjM0tx9xmtjAmVdKkkk5VDirnRhjOj8ll17swpd54tzL-U1fG6dFgonc7YCkIrtiWtuxFx2589d5gqPXKBYtladZYNUHTXKScKwm72rRDra9C8Dj766agd471UneO9c6xBqnhO3b-86GZrrD4C_1KbYHbDsDWydah18E6XFssnEdb66Jy_3_4AgcHi-Q</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Lamsoul, Isabelle</creator><creator>Uttenweiler-Joseph, Sandrine</creator><creator>Moog-Lutz, Christel</creator><creator>Lutz, Pierre G.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-7769-5627</orcidid><orcidid>https://orcid.org/0000-0001-9019-4766</orcidid><orcidid>https://orcid.org/0000-0003-0590-9101</orcidid></search><sort><creationdate>20160301</creationdate><title>Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?</title><author>Lamsoul, Isabelle ; Uttenweiler-Joseph, Sandrine ; Moog-Lutz, Christel ; Lutz, Pierre G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c512t-89d11a09de35e827d0fd260e29a9d1009ac7c3e7c5cdaa498a481b970973a6a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cullin Proteins - metabolism</topic><topic>Cullin RING ligase</topic><topic>E3 ubiquitin ligase</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Models, Biological</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Proteasome Endopeptidase Complex - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Therapeutic targets</topic><topic>Ubiquitin - metabolism</topic><topic>Ubiquitin-proteasome system</topic><topic>Ubiquitin-Protein Ligases - metabolism</topic><topic>Ubiquitination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamsoul, Isabelle</creatorcontrib><creatorcontrib>Uttenweiler-Joseph, Sandrine</creatorcontrib><creatorcontrib>Moog-Lutz, Christel</creatorcontrib><creatorcontrib>Lutz, Pierre G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamsoul, Isabelle</au><au>Uttenweiler-Joseph, Sandrine</au><au>Moog-Lutz, Christel</au><au>Lutz, Pierre G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>122</volume><spage>339</spage><epage>347</epage><pages>339-347</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Ubiquitylation is a reversible post-translational modification of proteins that controls a myriad of functions and cellular processes. It occurs through the sequential action of three distinct enzymes. E3 ubiquitin ligases (E3s) play the role of conductors of the ubiquitylation pathway making them attractive therapeutic targets. This review is dedicated to the largest family of multimeric E3s, the Cullin-RING E3 (CRL) family and more specifically to cullin 5 based CRLs that remains poorly characterized.
•CRLs are key players of the ubiquitylation pathway.•CRL activity is highly regulated.•CRL5s targeted specific protein substrates to degradation by the proteasome.•CRLs that belong to the largest family of E3s represent promising drug targets.</abstract><cop>France</cop><pub>Elsevier B.V</pub><pmid>26253693</pmid><doi>10.1016/j.biochi.2015.08.003</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7769-5627</orcidid><orcidid>https://orcid.org/0000-0001-9019-4766</orcidid><orcidid>https://orcid.org/0000-0003-0590-9101</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9084 |
| ispartof | Biochimie, 2016-03, Vol.122, p.339-347 |
| issn | 0300-9084 1638-6183 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02406392v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Agents - therapeutic use Cullin Proteins - metabolism Cullin RING ligase E3 ubiquitin ligase Humans Life Sciences Models, Biological Neoplasms - drug therapy Neoplasms - metabolism Proteasome Endopeptidase Complex - metabolism Signal Transduction - drug effects Therapeutic targets Ubiquitin - metabolism Ubiquitin-proteasome system Ubiquitin-Protein Ligases - metabolism Ubiquitination |
| title | Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T03%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cullin%205-RING%20E3%20ubiquitin%20ligases,%20new%20therapeutic%20targets?&rft.jtitle=Biochimie&rft.au=Lamsoul,%20Isabelle&rft.date=2016-03-01&rft.volume=122&rft.spage=339&rft.epage=347&rft.pages=339-347&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2015.08.003&rft_dat=%3Cproquest_hal_p%3E1764339803%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1764339803&rft_id=info:pmid/26253693&rft_els_id=S0300908415002503&rfr_iscdi=true |